ERJ-500

A new, vasoactive hybrid aspirin containing nitrogen monoxide-releasing molsidomine moiety

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

1.	Borbás, Anikó: 1 article (04/2019)
2.	Csávás, Magdolna: 1 article (04/2019)
3.	Czompa, Attila: 1 article (04/2019)
4.	Herczeg, Mihály: 1 article (04/2019)
5.	Herczegh, Pál: 1 article (04/2019)
6.	Lekli, István: 1 article (04/2019)
7.	Szabados-Fürjesi, Péter: 1 article (04/2019)
8.	Szőke, Kitti: 1 article (04/2019)
9.	Tósaki, Árpád: 1 article (04/2019)

1.	Ischemia 04/01/2019 - "Furthermore, a decreased infarct size was also noticed in ERJ-500 treated hearts after ischemia/reperfusion. "
2.	Infarction (Infarctions) 04/01/2019 - "Furthermore, a decreased infarct size was also noticed in ERJ-500 treated hearts after ischemia/reperfusion. "